I
Inveox
Biotech & Life Sciences · Garching bei München, Germany · Founded 2017
Develops systems for the digitization, automation and networking of pathology laboratories MoreLess
Inveox specializes in automating pathology labs to improve patient safety, increase lab efficiency, and unlock the potential of big data in cancer diagnostics. The company operates in the healthcare sector, focusing on pathology labs that handle tissue samples for cancer diagnosis. Inveox's core products include intelligent sample containers with integrated filters for automated assembly, an automation device that identifies and photographs tissue samples, and an encrypted web platform for seamless communication between clinics and labs. The business model revolves around selling these automated solutions to pathology labs, thereby generating revenue through product sales and potential service contracts. By streamlining the sample handling process, Inveox reduces the risk of misdiagnosis and enhances the speed and reliability of cancer testing, ultimately contributing to better patient outcomes and advancing cancer research.
Keywords: pathology automation, patient safety, lab efficiency, cancer diagnostics, intelligent containers, data integration, healthcare technology, sample handling, misdiagnosis prevention, lab communication.
Company overview
Inveox company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Garching bei München, Germany
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 65.9
Valuation & funding
Inveox funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Aug 2019 | $19M | $75M | Undisclosed | ↗ |
| SUPPORT PROGRAM✓Other financing | Oct 2018 | $2K | — | EIT Health | — |
| SUPPORT PROGRAM✓Other financing | Jul 2018 | $55K | — | EIT Health | — |
| EARLY VC✓Equity / VC | Jan 2018 | $5.5M | $22M | Undisclosed | — |
| SPINOUT✓Other financing | Feb 2017 | $0 | — | Technical University Munich | — |
| ANGEL✓Equity / VC | Jan 2017 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Inveox website traffic
Latest recorded traffic for Inveox is 10 monthly website visits, down 97.6% over the last three months. Inveox's team declined 12.5% over the past year.
Comparisons
Inveox compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Inveox's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Inveox has talent and traffic
team presence
In the news
Latest news about Inveox
Recent press, funding announcements, and product moves mentioning Inveox — open to read from the original sources.
Market sentiment
What the market is saying about Inveox
An AI-synthesized read of the highest-engagement posts about Inveox on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Inveox’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.